BUY Aarti Drugs — Siddharth Rai Mangala, 01 Sept 2026

bySiddharth Rai MangalaHorizon: NA (inferred Swing (≤2wk))1 Sept 2026via Zee Business (Live)

Entry₹428Inferred

Target₹445

Stop loss₹409-4.44% risk

CMP₹431.652d ago

Active+0.85%+3.09%upside left 9d left

Follow Siddharth Rai Mangala for new calls(30% target hit, 89 closed calls)Get alerts Watch AARTIDRUGS for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Sept, 1:37 am IST

3 supporting1 neutral0 opposing

Supports the BUY call (3)

MACD above its signal line — bullish momentum

Technicals · macd·6 Sept · today

Aarti Drugs Ltd's Board of Directors has approved the company's Performance Stock Option Plan 2026. This plan is likely to incentivize employees and align their interests with the company's performanc

BSE · Board Meeting·27 Aug · 1w ago

Aarti Drugs Targets 15-16% EBITDA Margin On Higher Sayakha Utilisation, Metformin Volumes: CFO

NewsNdtv-Profit·24 Aug · 2w ago

Neutral / worth noting (1)

The Board of Directors approved the 'Aarti Drugs Limited Performance Stock Option Plan 2026' to create and grant up to 8,00,000 stock options convertible into equity shares. This is subject to member

NSE · Outcome of Board Meeting·27 Aug · 1w ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

BUY Aarti Drugs Limited — Siddharth Rai Mangala

AI Assessment